Patent intelligence · US
US 11578066
Fluoroalkyl-oxadiazoles and uses thereof
Fluoroalkyl-oxadiazoles and uses thereof
Patent details — US 11578066
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2023
- Expiration
- Feb 9, 2043
- Applicant
- Tenaya Therapeutics, Inc.
- Claims
- 28
- CPC classes
- A61P, A61P25/00
Quick answer
US 11578066 (Fluoroalkyl-oxadiazoles and uses thereof) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tenaya Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61P, A61P25/00
More from Tenaya Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12312345
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 12201617
HDAC6 inhibitors for treatment of metabolic disease and HFpEF
granted -
US 12168778
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 12151001
Optimized expression cassettes for gene therapy
granted -
US 12104165
Adeno-associated virus with engineered capsid
granted -
US 11926622
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 11913012
Cardiac cell reprogramming with myocardin and ASCL1
granted -
US 11781156
Plakophillin-2 gene therapy methods and compositions
granted
Frequently asked questions
What is US patent 11578066?
US 11578066 (Fluoroalkyl-oxadiazoles and uses thereof) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11578066?
Tenaya Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 11578066 expire?
Our index shows an expiration date of Feb 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.